Showing results (131-140 of 141) with videos related to

Sort By:
Pageof 15
AIDS (London, England)|November 15, 2023
Initial antiretroviral therapy regimen and risk of heart failureMichael J Silverberg, Noel Pimentel, Wendy A Leyden, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 26, 2023
Fracture Risk and Association With TDF Use Among People With HIV in Large Integrated Health SystemsRulin C Hechter, Hui Zhou, Wendy A Leyden, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|September 13, 2024
Excess Mortality in Persons with Concurrent HIV and Cancer Diagnoses: A Retrospective Cohort StudyKamaria L Lee, Varada Sarovar, Jennifer O Lam, et al.
Annals of Internal Medicine|November 10, 2015
Sofosbuvir With Velpatasvir in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection: A Randomized TrialGregory T Everson, William J Towner, Mitchell N Davis, et al.
Annals of Internal Medicine|November 10, 2015
Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection: A Randomized TrialStephen Pianko, Steven L Flamm, Mitchell L Shiffman, et al.
The New England Journal of Medicine|November 17, 2015
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 InfectionJordan J Feld, Ira M Jacobson, Christophe Hézode, et al.
Lancet (London, England)|August 1, 2014
All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort studyMichael Manns, Stanislas Pol, Ira M Jacobson, et al.
The New England Journal of Medicine|May 28, 2020
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19Jason D Goldman, David C B Lye, David S Hui, et al.
The New England Journal of Medicine|July 22, 2015
Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1Susanna Naggie, Curtis Cooper, Michael Saag, et al.
Pageof 15